Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $12.67.

A number of brokerages recently issued reports on IMUX. HC Wainwright began coverage on Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price on the stock. StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research report on Friday, January 31st. Finally, D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a research report on Tuesday, January 7th.

Insider Buying and Selling at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares in the company, valued at $100,395. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IMUX. Virtu Financial LLC bought a new position in shares of Immunic during the 3rd quarter worth approximately $50,000. HB Wealth Management LLC bought a new position in shares of Immunic during the 4th quarter worth approximately $81,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the period. Finally, State Street Corp boosted its stake in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Immunic Price Performance

NASDAQ IMUX opened at $0.98 on Thursday. The firm has a market cap of $88.72 million, a P/E ratio of -0.80 and a beta of 1.87. The stock’s 50-day moving average is $1.08 and its 200-day moving average is $1.29. Immunic has a one year low of $0.92 and a one year high of $2.11.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, November 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). During the same quarter last year, the business earned ($0.51) earnings per share. Equities analysts anticipate that Immunic will post -0.94 EPS for the current year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.